68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients

We evaluated the clinical utility of Ga-68-PSMA-11 PET/CT for staging and risk stratification of treatment-naive prostate cancer (PCa) and metastatic castrateresistant prostate cancer (mCRPC). Twenty- two consecutive patients with treatmentnaive PCa and 18 with mCRPC were enrolled. Ga-68- PSMA-11 PET/CT and magnetic resonance imaging (MRI) were performed for the evaluation of primary prostatic lesions, and bone scans were used for evaluation bone metastasis. Among the 40 patients, 37 (92.5% [22 treatment- naive PCa, 15 mCRPC]) showed PSMA- avid lesions on 68Ga- PSMA- 11 images. Only 3 patients with stable mCRPC after chemotherapy were negative for PSMA. The sensitivity, specificity and accuracy of 68Ga- PSMA- 11 imaging were 97.3%, 100.0% and 97.5%, respectively. The maximum standardized uptake (SUVmax) of prostatic lesions was 17.09 +/- 11.08 and 13.33 +/- 12.31 in treatment- naive PCa and mCRPC, respectively. 68Ga- PSMA- 11 revealed 105 metastatic lymph nodes in 15 patients; the SUVmax was 16.85 +/- 9.70 and 7.54 +/- 5.20 in treatment- naive PCa and mCRPC, respectively. 68Ga- PSMA- 11 PET/CT also newly detected visceral metastasis in 9 patients (22.5%) and bone metastasis in 29 patients (72.5%). Ga-68-PSMA-11 PET/CT exhibits potential for staging and risk stratification in naive PCa, as well as improved sensitivity for detection of lymph node and remote metastasis.